Vida Ventures is a bio-coastal life sciences company transforming biomedical innovations into therapies.
Location: United States, Massachusetts, Boston
Investors 2
| Date | Name | Website |
| - | Old Silver... | oldsilverv... |
| - | Top Tier C... | ttcp.com |
Mentions in press and media 26
| Date | Title | Description |
| 04.03.2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding. The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| 03.03.2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| 08.01.2026 | Poplar Therapeutics Launched With $50 Million Series A To Advance Anti-IgE Therapy for Multiple Atopic Conditions | Poplar Therapeutics has launched as a clinical-stage immunology company with a $50 million Series A financing to advance PHB-050, a next-generation anti-IgE antibody being developed for food allergy and other atopic conditions such as asthm... |
| 08.01.2026 | Poplar Therapeutics Raises $50M in Series A Funding | Poplar Therapeutics, Inc. (previously known as Phylaxis Bioscience), a Boston, MA-based clinical-stage immunology company, raised $50m in Series A financing. The round was led by SR One, Vida Ventures and Platanus. The company intends to us... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge** ** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures -- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
Show more